journal article·2021-12-22

Assembly Transformation Jointly Driven by the LAP Enzyme and GSH Boosting Theranostic Capability for Effective Tumor Therapy

Anna Wang, Jing Fang, Shuyue Ye, Qiulian Mao, Yan Zhao, Chaoxiang Cui, Yuqi Zhang, Yali Feng, Jiachen Li, Lei He, Ling Qiu, Haibin Shi

ACS Applied Materials & Interfaces· Volume 13· Issue 50
Publisher page

Abstract

Developing intelligent and morphology-transformable nanomaterials that can spatiotemporally undergo stimulus-responsive size transformation holds great promise for improving the tumor delivery efficiency of drugs in vivo. Here, we report a smart size-transformable theranostic probe Ce6-Leu consisting of a leucine amino peptidase (LAP) and glutathione (GSH) dual-responsive moiety, an 1,2-aminothiol group, and a clinically used photosensitizer Ce6. This probe tends to self-assemble into uniform nanoparticles with an initial size of ∼80 nm in aqueous solution owing to the amphiphilic feature. Surprisingly, taking advantage of the biocompatible CBT-Cys condensation reaction, the large nanoprobes can be transformed into tiny nanoparticles (∼23 nm) under the joint action of LAP and GSH in a tumor microenvironment, endowing them with great tumor accumulation and deep tissue penetration. Concomitantly, this LAP/GSH-driven disassembly and size shrinkage of Ce6-Leu can also activate the fluorescence/magnetic resonance signals and the photodynamic effect for enhanced multimodal imaging-guided photodynamic therapy of human liver HepG2 tumors in vivo. More excitingly, the Mn2+-chelating probe (Ce6-Leu@Mn2+) was demonstrated to have the capability to catalyze endogenous H2O2 to persistently release O2 at the hypoxic tumor site, as a consequence improving the oxygen supply to boost the radiotherapy effect. We thus believe that this LAP/GSH-driven size-transformable nanosystem would offer a novel advanced technology to improve the drug delivery efficiency for achieving precise tumor diagnosis and treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Peptidase Inhibition and Analysis · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), and Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, P. R. China

Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, P. R. China

Funding

State Key Laboratory of Radiation Medicine and Protection · National Natural Science Foundation of China · Priority Academic Program Development of Jiangsu Higher Education Institutions · Key Research and Development Program of Social Development of Jiangsu Province · Open Program of NHC Key Laboratory of Nuclear Medicine and Jiangsu Key Laboratory of Molecular Nuclear Medicine

References (83)

Show source-provided references
1. 10.1002/ijc.2921010.1002/ijc.29210 ↗
2. 10.3322/caac.2165410.3322/caac.21654 ↗
3. 10.1038/nrgastro.2016.19310.1038/nrgastro.2016.193 ↗
4. 10.1158/0008-5472.CAN-07-687110.1158/0008-5472.CAN-07-6871 ↗
5. 10.1038/nrd400310.1038/nrd4003 ↗
6. 10.1158/0008-5472.CAN-07-661110.1158/0008-5472.CAN-07-6611 ↗
7. 10.1016/S1470-2045(04)01529-310.1016/S1470-2045(04)01529-3 ↗
8. 10.1136/thx.2006.06114310.1136/thx.2006.061143 ↗
9. 10.1038/s41551-018-0262-610.1038/s41551-018-0262-6 ↗
10. 10.1016/j.canlet.2017.01.04010.1016/j.canlet.2017.01.040 ↗
11. 10.1038/nm110010.1038/nm1100 ↗
12. 10.1038/nature1262510.1038/nature12625 ↗
13. 10.1038/nature1262410.1038/nature12624 ↗
14. 10.1016/j.tibtech.2009.12.00710.1016/j.tibtech.2009.12.007 ↗
15. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
16. 10.1038/nrd198410.1038/nrd1984 ↗
17. 10.1016/j.canlet.2014.03.01310.1016/j.canlet.2014.03.013 ↗
18. 10.1021/acs.chemrev.5b0014810.1021/acs.chemrev.5b00148 ↗
19. 10.1007/s11426-018-9397-510.1007/s11426-018-9397-5 ↗
20. 10.1021/acs.chemrev.7b0025810.1021/acs.chemrev.7b00258 ↗
21. 10.1021/acs.accounts.8b0039810.1021/acs.accounts.8b00398 ↗
22. 10.1002/smll.20200472310.1002/smll.202004723 ↗
23. 10.1021/jacs.0c1024510.1021/jacs.0c10245 ↗
24. 10.1039/D1SC01073E10.1039/D1SC01073E ↗
25. 10.1126/sciadv.aax093710.1126/sciadv.aax0937 ↗
26. 10.1038/s41467-018-07490-610.1038/s41467-018-07490-6 ↗
27. 10.1002/anie.20200098310.1002/anie.202000983 ↗
28. 10.1021/acs.nanolett.1c0102910.1021/acs.nanolett.1c01029 ↗
29. 10.1021/acsnano.0c0138810.1021/acsnano.0c01388 ↗
30. 10.1002/ange.20210260110.1002/ange.202102601 ↗
31. 10.1021/jacs.0c0759410.1021/jacs.0c07594 ↗
32. 10.1038/nchem.192010.1038/nchem.1920 ↗
33. 10.1021/acsnano.6b0341210.1021/acsnano.6b03412 ↗
34. 10.1126/sciadv.aba319010.1126/sciadv.aba3190 ↗
35. 10.1021/acsnano.9b0820910.1021/acsnano.9b08209 ↗
36. 10.1038/s41467-019-12848-510.1038/s41467-019-12848-5 ↗
37. 10.1002/anie.20201512610.1002/anie.202015126 ↗
38. Campbell R. B. · Cancer Res. · 2002 · 62 · 6831
39. 10.1016/j.biomaterials.2015.09.01810.1016/j.biomaterials.2015.09.018 ↗
40. 10.1038/nrc.2017.9310.1038/nrc.2017.93 ↗
41. 10.1021/acs.accounts.9b0012610.1021/acs.accounts.9b00126 ↗
42. 10.1146/annurev-bioeng-071811-15012410.1146/annurev-bioeng-071811-150124 ↗
43. 10.1002/adhm.20180035910.1002/adhm.201800359 ↗
44. 10.1002/anie.20200914110.1002/anie.202009141 ↗
45. 10.1002/anie.20200110710.1002/anie.202001107 ↗
46. 10.1002/adma.20150180310.1002/adma.201501803 ↗
47. 10.1016/j.addr.2012.01.00210.1016/j.addr.2012.01.002 ↗
48. 10.1021/jacs.7b0890010.1021/jacs.7b08900 ↗
49. Feng L. · Natl. Sci. Rev. · 2017 · 5 · 26910.1093/nsr/nwx062 ↗
50. 10.1038/nnano.2016.7210.1038/nnano.2016.72 ↗
51. 10.1016/j.semcancer.2008.03.01110.1016/j.semcancer.2008.03.011 ↗
52. 10.1182/blood.V97.2.39310.1182/blood.V97.2.393 ↗
53. 10.1002/anie.20161202010.1002/anie.201612020 ↗
54. 10.1038/nbt.283810.1038/nbt.2838 ↗
55. 10.1021/acs.chemrev.8b0062610.1021/acs.chemrev.8b00626 ↗
56. 10.1002/anie.20181287810.1002/anie.201812878 ↗
57. 10.1002/ange.20161214210.1002/ange.201612142 ↗
58. 10.1002/adma.20160489410.1002/adma.201604894 ↗
59. 10.1016/1011-1344(93)06974-810.1016/1011-1344(93)06974-8 ↗
60. 10.1007/s10103-010-0781-110.1007/s10103-010-0781-1 ↗
61. 10.1002/adma.20180135010.1002/adma.201801350 ↗
62. 10.1038/nmat298610.1038/nmat2986 ↗
63. 10.1021/cr900236h10.1021/cr900236h ↗
64. 10.1002/anie.20130338710.1002/anie.201303387 ↗
65. 10.1038/srep3133910.1038/srep31339 ↗
66. 10.1016/j.nantod.2020.10103010.1016/j.nantod.2020.101030 ↗
67. 10.1016/j.jconrel.2018.07.02710.1016/j.jconrel.2018.07.027 ↗
68. 10.1002/adfm.20190008410.1002/adfm.201900084 ↗
69. 10.1002/adfm.20190077310.1002/adfm.201900773 ↗
70. 10.1038/ncomms571210.1038/ncomms5712 ↗
71. 10.1002/anie.20191257410.1002/anie.201912574 ↗
72. 10.1039/C9CC06839B10.1039/C9CC06839B ↗
73. 10.1039/C8NR05061A10.1039/C8NR05061A ↗
74. 10.1021/ja039832y10.1021/ja039832y ↗
75. 10.1038/463977a10.1038/463977a ↗
76. 10.1021/jacs.8b0416910.1021/jacs.8b04169 ↗
77. 10.1021/acs.chemrev.8b0036310.1021/acs.chemrev.8b00363 ↗
78. 10.1021/acsnano.5b0064010.1021/acsnano.5b00640 ↗
79. 10.1038/s41467-018-06093-510.1038/s41467-018-06093-5 ↗
80. 10.1039/C9SC00747D10.1039/C9SC00747D ↗
81. 10.1021/acsami.9b1508310.1021/acsami.9b15083 ↗
82. 10.1038/nrc239710.1038/nrc2397 ↗
83. 10.1038/nrc306410.1038/nrc3064 ↗